LFMDP | Ticker Profile - Titan Protect

LFMDP

LifeMD, Inc.

Healthcare · Health Information Services · NGM

$23.60

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 57.1%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

N/A

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.4%

Year-over-year revenue change

Profit Margin

2.9%

How much profit the company keeps from each dollar of revenue

ROE

-238.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About LifeMD, Inc.

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

https://lifemd.com

Country: United States Employees: 347 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.653

Good returns relative to risk taken

Kelly Fraction

-0.0673

No positive edge detected — the data suggests staying out

Calmar Ratio

0.703

Acceptable balance between returns and drawdown risk

Annual Return

14.1%

Historical annualised return based on price data

Max Drawdown

-20.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.02

Significantly more volatile than the market

52W High

$24.75

5% below the year high

52W Low

$18.50

28% above the year low

Avg Volume

1,970

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

935.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.26

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

41.05

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.04

Adequate but worth monitoring

Quick Ratio

0.89

Like current ratio but excludes inventory — stricter test

Gross Margin

86.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-17.8%

Profit from core operations before interest and tax

Free Cash Flow

$-4,156,398

Negative — the business is spending more than it generates

Revenue (TTM)

$193M

Total revenue over the last 12 months

Net Income

$-21,299,564

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go